plerixafor has been researched along with Nervous System Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antunes, AR; Ruscher, K; van der Maten, G; Walter, HL; Wieloch, T | 1 |
| Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL | 1 |
2 other study(ies) available for plerixafor and Nervous System Disorders
| Article | Year |
|---|---|
Treatment with AMD3100 attenuates the microglial response and improves outcome after experimental stroke.
Topics: Animals; Benzylamines; Brain Infarction; Calcium-Binding Proteins; Cyclams; Cytokines; Disease Models, Animal; Gene Expression Regulation; Green Fluorescent Proteins; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Microglia; Microscopy, Confocal; Nervous System Diseases; Neuroprotective Agents; Photons; Receptors, Interleukin-8A; Recovery of Function; Stroke | 2015 |
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles | 2012 |